NEUROFIBROMATOSIS TYPE 1 (NF1)-RELATED PLEXIFORM NEUROFIBROMAS (PNS)

Clinical trials for NEUROFIBROMATOSIS TYPE 1 (NF1)-RELATED PLEXIFORM NEUROFIBROMAS (PNS) explained in plain language.

Never miss a new study

Get alerted when new NEUROFIBROMATOSIS TYPE 1 (NF1)-RELATED PLEXIFORM NEUROFIBROMAS (PNS) trials appear

Sign up with your email to follow new studies for NEUROFIBROMATOSIS TYPE 1 (NF1)-RELATED PLEXIFORM NEUROFIBROMAS (PNS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New pill tested to shrink painful NF1 tumors

Disease control Recruiting now

This early-stage study is testing a new oral medication called PAS-004 in adults with Neurofibromatosis Type 1 (NF1) who have painful, inoperable, or recurring plexiform neurofibroma tumors. The main goals are to find a safe dose, understand the side effects, and see if the drug …

Matched conditions: NEUROFIBROMATOSIS TYPE 1 (NF1)-RELATED PLEXIFORM NEUROFIBROMAS (PNS)

Phase: PHASE1 • Sponsor: Pasithea Therapeutics Corp. • Aim: Disease control

Last updated Apr 01, 2026 14:41 UTC

NEUROFIBROMATOSIS TYPE 1 (NF1)-RELATED PLEXIFORM NEUROFIBROMAS (PNS)

Get alerted when new NEUROFIBROMATOSIS TYPE 1 (NF1)-RELATED PLEXIFORM NEUROFIBROMAS (PNS) trials appear

New pill tested to shrink painful NF1 tumors